跳至主要内容
临床试验/NCT04016610
NCT04016610已完成不适用

Proof of Concept (POC) Study of the Soliton's Acoustic Scar Reduction (ASR) Treatment Using Rapid Acoustic Pulse (RAP) Device for the Treatment of Keloid Scar

Soliton2 个研究点 分布在 1 个国家目标入组 9 人开始时间: 2019年7月9日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
Soliton
入组人数
9
试验地点
2
主要终点
Procedure Safety

研究概览

简要总结

To evaluate the safety, and efficacy of the ASR device for the temporary improvement in the appearance of a keloids.

详细描述

To evaluate the safety, and efficacy of the ASR device for the temporary improvement in the appearance of a keloids. To demonstrate improvement in the keloid scars, without unexpected adverse events (UAEs) and serious adverse events (SAEs) directly attributable to the ASR device or treatment.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Device Feasibility
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Male or female older than 18 at the screening visit;
  • The participant is healthy, as determined by the investigator based on a medical evaluation including medical history;
  • The participant has a keloid that is easily delineated photographically located on the chest, back, trunk or upper arms and legs.
  • Keloid size greater than 1 cm and less than 8 cm in length, with a height of at least 2 mm.
  • Keloids less than 5 years old
  • Body Mass Index (B.M.I.) is > 20
  • Participant is willing to not undergo any other keloid treatments for a period of 12 months following ASR treatment.
  • Participant is willing to participate in study and adhere to follow-up schedule.
  • Participant is able to read and comprehend English or Spanish.
  • Participant has completed the Informed Consent Form.

排除标准

  • Participant had treatments, including topical steroids, to the keloid being treated in the study in the prior 12 months.
  • Participant is unwilling to have research photos taken of treatment areas in the presence of Sponsor's researchers.
  • Participant is unwilling to have ASR treatment provided in the presence of Sponsor's researchers.
  • Participant is pregnant or planning to become pregnant during the duration of the study.
  • Metal or plastic implants near the area of the treatment (vascular stent, plates and screws, chest wires, hips, elbows, knees, etc.).
  • Active electronic implants such as pacemakers, defibrillators, cochlear implants, nerve/brain stimulators, drug pump, etc.
  • Medical disorder that would hinder the wound healing or immune response (no blood disorder, etc.).
  • History of coagulopathy(ies) and/or on anticoagulant medication.
  • Skin disorders (skin infections or rashes, extensive scarring, psoriasis, etc.) in the treatment area.
  • Current smoker.
  • Any surgical procedure in the prior 3 months, or planned during the duration of the study.

结局指标

主要结局

Procedure Safety

时间窗: 12 weeks

The safety endpoint will be met if all treated participants are free from unexpected adverse events and serious adverse events directly attributable to the ASR device or treatment.

次要结局

  • Treatement Tolerability(12 weeks)

研究者

发起方
Soliton
申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验